Ipatasertib

Generic Name
Ipatasertib
Brand Names
-
Drug Type
Small Molecule
Chemical Formula
C24H32ClN5O2
CAS Number
1001264-89-6
Unique Ingredient Identifier
524Y3IB4HQ
Background

Ipatasertib has been used in trials studying the treatment of Cancer, Neoplasms, Solid Cancers, Breast Cancer, and Gastric Cancer, among others.

Associated Conditions
-
Associated Therapies
-
Clinical Trials
Related News

A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors

First Posted Date
2021-06-18
Last Posted Date
2024-12-19
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
176
Registration Number
NCT04931342
Locations
🇫🇷

CHU Besançon - Hôpital Jean Minjoz, Besançon Cedex, France

🇫🇷

Institut Bergonie; Oncologie, Bordeaux, France

🇫🇷

Centre Francois Baclesse; Oncologie, Caen, France

and more 51 locations

A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer

First Posted Date
2021-03-17
Last Posted Date
2024-12-06
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
510
Registration Number
NCT04802759
Locations
🇺🇸

Regional Cancer Care Associates LLC (RCCA) - Freehold Location, Freehold, New Jersey, United States

🇺🇸

Regional Cancer Care Associates LLC ? Howell Division, Howell, New Jersey, United States

🇺🇸

Levine Cancer Institute, Charlotte, North Carolina, United States

and more 25 locations

Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer

First Posted Date
2021-02-03
Last Posted Date
2023-11-13
Lead Sponsor
David VanderWeele
Target Recruit Count
6
Registration Number
NCT04737109
Locations
🇺🇸

Penn State Cancer Institute, Hershey, Pennsylvania, United States

🇺🇸

Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States

🇺🇸

Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States

Fulvestrant and Ipatasertib for Advanced HER-2 Negative and Estrogen Receptor Positive (ER+) Breast Cancer Following Progression on First Line CDK 4/6 Inhibitor and Aromatase Inhibitor

Phase 3
Active, not recruiting
Conditions
Breast Cancer
Interventions
Drug: Ipatasertib
Drug: Fulvestrant
Other: Placebo
First Posted Date
2020-12-02
Last Posted Date
2024-07-31
Lead Sponsor
Canadian Cancer Trials Group
Target Recruit Count
250
Registration Number
NCT04650581
Locations
🇨🇦

QEII Health Sciences Centre, Halifax, Nova Scotia, Canada

🇨🇦

Centre Integre de Sante et de Services Sociaux, Greenfield Park, Quebec, Canada

🇨🇦

CHUM-Centre Hospitalier de l'Universite de Montreal, Montreal, Quebec, Canada

and more 36 locations

A Study Evaluating Targeted Therapies in Participants Who Have Advanced Solid Tumors With Genomic Alterations or Protein Expression Patterns Predictive of Response

First Posted Date
2020-11-17
Last Posted Date
2024-03-07
Lead Sponsor
Genentech, Inc.
Target Recruit Count
252
Registration Number
NCT04632992
Locations
🇺🇸

Kaiser Permanente - San Leandro Medical Center, San Leandro, California, United States

🇺🇸

Ascension St. John Hospital, Detroit, Michigan, United States

🇺🇸

Sarah Cannon Research Institute, Nashville, Tennessee, United States

and more 42 locations

The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy

First Posted Date
2020-10-19
Last Posted Date
2023-10-03
Lead Sponsor
Fondazione per la Medicina Personalizzata
Target Recruit Count
400
Registration Number
NCT04591431
Locations
🇮🇹

I.R.S.T. Srl Irccs, Meldola, Italy

🇮🇹

Ospedale Classificato Sacro Cuore - Don Calabria, Negrar, Italy

🇮🇹

I.R.C.C.S. Istituto Oncologico Veneto, Padova, Italy

and more 34 locations

Tumor-Agnostic Precision Immuno-Oncology and Somatic Targeting Rational for You (TAPISTRY) Platform Study

First Posted Date
2020-10-19
Last Posted Date
2024-11-22
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
920
Registration Number
NCT04589845
Locations
🇺🇸

Southern Cancer Center, Daphne, Alabama, United States

🇺🇸

Western Regional Medical Center at Cancer Treatment Centers of America, Goodyear, Arizona, United States

🇺🇸

Hoag Memorial Hospital, Newport Beach, California, United States

and more 171 locations

To Evaluate the Safety and Efficacy of Ipatasertib (GDC-0068) in Combination With Paclitaxel in Platinum-resistant Recurrent Epithelial Ovarian Cancer

Phase 2
Withdrawn
Conditions
Ovarian Neoplasms
Interventions
Drug: Ipatasertib
Drug: Paclitaxel
First Posted Date
2020-09-24
Last Posted Date
2020-10-06
Lead Sponsor
Icahn School of Medicine at Mount Sinai
Registration Number
NCT04561817
Locations
🇺🇸

Dubin Breast Center, New York, New York, United States

CRAFT: the NCT-PMO-1602 Phase II Trial

First Posted Date
2020-09-16
Last Posted Date
2024-12-11
Lead Sponsor
German Cancer Research Center
Target Recruit Count
175
Registration Number
NCT04551521
Locations
🇩🇪

Charité - Universitätsmedizin Berlin, Berlin, Germany

🇩🇪

Nationales Centrum für Tumorerkrankungen (NCT), Heidelberg, Germany

🇩🇪

Universitätsklinikum Freiburg, Freiburg, Germany

and more 5 locations

A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

First Posted Date
2020-07-24
Last Posted Date
2024-07-03
Lead Sponsor
Alliance Foundation Trials, LLC.
Target Recruit Count
148
Registration Number
NCT04486352
Locations
🇺🇸

Washington University School of Medicine Siteman Cancer Center, Saint Louis, Missouri, United States

🇺🇸

Englewood Health, Englewood, New Jersey, United States

🇺🇸

Atlantic Health Systems/Morristown Medical Center, Morristown, New Jersey, United States

and more 18 locations
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy